SAM
ANAB icon

Senzar Asset Management’s AnaptysBio ANAB Stock Holding History

Senzar Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-15,970
Closed -$1.14M – 2
2018
Q2 		$1.14M Sell
15,970
-9,230
-37% -$774K 3.27% 12
2018
Q1 		$2.62M Buy
+25,200
New +$2.84M 0.83% 30

Other funds holding ANAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Senzar Asset Management's ANAB Position: Q3 2018 in Review

Senzar Asset Management sold out of AnaptysBio (ANAB) in Q3 2018, closing a stake of 15,970 shares — an estimated $1.14M sold.

Senzar Asset Management first reported a position in ANAB in Q1 2018 and held it in 2 quarters. The position peaked at $2.62M in Q1 2018. 129 funds tracked by Wall St. Rank hold ANAB as of Q3 2018.

  • Senzar Asset Management reported no remaining AnaptysBio position as of Q3 2018 after selling out during the quarter.
  • Senzar Asset Management sold 15,970 AnaptysBio shares in Q3 2018, an estimated $1.14M.
  • Senzar Asset Management first reported a position in AnaptysBio in Q1 2018 and held it in 2 quarters.
  • Senzar Asset Management's AnaptysBio position peaked at $2.62M in Q1 2018.
  • 129 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2018.

Based on Senzar Asset Management's 13F filing for Q3 2018.